Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.

Abstract	Adjuvant chemotherapy (AC) following pancreatic carcinoma (PC) resection improves overall survival (OS). A systematic review identified 10 phase-2/3 studies investigating AC in 3644 patients looking at the influence of nodal and resection status. AC significantly improved disease free survival, OS and 5-year odds of death risk. There was greater survival benefit in patients PS 0 and with body/tail tumors. There was a nonsignificant effect in N - /N + patients on OS and no difference between R0/R1 patients.
Authors	Nicola Flaum, Richard A Hubner, Juan W Valle, Eitan Amir, Mairéad G McNamara
Journal	Journal of surgical oncology (J Surg Oncol) Vol. 119 Issue 7 Pg. 932-940 (Jun 2019) ISSN: 1096-9098 [Electronic] United States
PMID	30838647 (Publication Type: Journal Article, Meta-Analysis, Systematic Review)
Copyright	© 2019 Wiley Periodicals, Inc.
Topics	Carcinoma, Pancreatic Ductal (drug therapy, surgery) Chemotherapy, Adjuvant Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Humans Lymph Node Excision Lymphatic Metastasis Margins of Excision Pancreatic Neoplasms (drug therapy, surgery) Randomized Controlled Trials as Topic Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!